Development of peptide vaccines for HLA-A24ィイD1+ィエD1 esophageal cancer patients.

A main objective of this res\project is to peptide vaccines useful for HLA-A24イイD1+イエD1 patients with esophageal c\。我们有五个已识别的肿瘤拒绝抗原（SART 1-SART 5）来自CDNA生理癌症细胞，该细胞被HLA-A24识别-受限制地从一个生理癌症患者衍生出来。SART-1、SART-2和SART-3肿瘤反应性抗原是最近识别的分子，同时保留两个已知的分子（Lck和PI 9）。SART-1，SART-2，SART-3和PI 9肿瘤-拒绝抗原在生理癌症中广泛表达的大多数，而Lck最好在生理癌症中表达。肽抗原是由CTLs识别的，并且那些能够识别HLA类I限制的CTLs来自外围血液单核细胞（PBMCs）的异位癌症患者也被识别为这些肿瘤-拒绝抗原。SART-1型D2690-698型D2或SART-1型D2736-744型D2肽目前被用作HLA-A24型癌症疫苗的临床研究，即HLA-A24型D1+型D1或A26型D1型D1型严重程度，位于Kurume大学医院。这些基本和临床研究将提供新的见解，以更好地理解T细胞介导的细胞识别的分子基础。继续，这些研究

A main objective of this research project is to develop of peptide vaccines useful for HLA-A24ィイD1+ィエD1 patients with esophageal cancer. We have identified five tumor-rejection antigens (SART1-SART5) from cDNA esophageal cancer cells that were recognized by HLA-A24-restricted m derived from an esophageal cancer patient. SART-1, SART-2, and SART-3 tumor rejective antigens were newly identified molecules, while the remaining two were known molecules (Lck and PI9). SART-1, SART-2, SART-3, and PI9 tumor-rejection antigens were broadly expressed in the majority of esophageal cancers, while Lck was preferentially expressed in metastatic esophageal cancers. Peptide antigens recognized by the CTLs, and those capable of inducing HLA-class I restricted CTLs from peripheral blood mononuclear cells (PBMCs) of esophageal cancer patients were also identified in these tumor-rejection antigens. SART-1ィイD2690-698ィエD2 or SART-1ィイD2736-744ィエD2 peptide is currently used for phase I clinical studies as cancer vaccines in HLA-A24ィイD1+ィエD1 or -A26ィイD1+ィエD1 esophageal respectively, in our Kurume University Hospital. These basic and clinical research shall provide new insight for better understanding of molecular basis of T cell-mediated recognition of cancer cells. Further, these studies